Aroa Biosurgery Ltd (ARX) - Net Assets
Based on the latest financial reports, Aroa Biosurgery Ltd (ARX) has net assets worth AU$80.93 Million AUD (≈ $57.26 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$95.27 Million ≈ $67.41 Million USD) and total liabilities (AU$14.34 Million ≈ $10.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Aroa Biosurgery Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$80.93 Million |
| % of Total Assets | 84.95% |
| Annual Growth Rate | 17.38% |
| 5-Year Change | 57.55% |
| 10-Year Change | 1330.9% |
| Growth Volatility | 176.24 |
Aroa Biosurgery Ltd - Net Assets Trend (2001–2025)
This chart illustrates how Aroa Biosurgery Ltd's net assets have evolved over time, based on quarterly financial data. Also explore ARX total asset value for the complete picture of this company's asset base.
Annual Net Assets for Aroa Biosurgery Ltd (2001–2025)
The table below shows the annual net assets of Aroa Biosurgery Ltd from 2001 to 2025. For live valuation and market cap data, see Aroa Biosurgery Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | AU$84.59 Million ≈ $59.85 Million |
-2.87% |
| 2024-03-31 | AU$87.09 Million ≈ $61.62 Million |
-8.69% |
| 2023-03-31 | AU$95.38 Million ≈ $67.49 Million |
+2.11% |
| 2022-03-31 | AU$93.40 Million ≈ $66.09 Million |
+73.96% |
| 2021-03-31 | AU$53.69 Million ≈ $37.99 Million |
-14.58% |
| 2020-03-31 | AU$62.86 Million ≈ $44.48 Million |
+445.60% |
| 2019-03-31 | AU$11.52 Million ≈ $8.15 Million |
+551.60% |
| 2018-03-31 | AU$1.77 Million ≈ $1.25 Million |
-71.85% |
| 2017-03-31 | AU$6.28 Million ≈ $4.44 Million |
+6.24% |
| 2016-03-31 | AU$5.91 Million ≈ $4.18 Million |
-14.62% |
| 2015-03-31 | AU$6.92 Million ≈ $4.90 Million |
-8.64% |
| 2014-03-31 | AU$7.58 Million ≈ $5.36 Million |
-15.81% |
| 2013-03-31 | AU$9.00 Million ≈ $6.37 Million |
-3.62% |
| 2012-03-31 | AU$9.34 Million ≈ $6.61 Million |
+96.38% |
| 2011-03-31 | AU$4.76 Million ≈ $3.37 Million |
+183.60% |
| 2010-03-31 | AU$1.68 Million ≈ $1.19 Million |
+107.40% |
| 2009-03-31 | AU$-22.65 Million ≈ $-16.02 Million |
-25.01% |
| 2008-03-31 | AU$-18.12 Million ≈ $-12.82 Million |
-159.78% |
| 2007-03-31 | AU$30.31 Million ≈ $21.44 Million |
-6.92% |
| 2006-03-31 | AU$32.56 Million ≈ $23.04 Million |
+113.82% |
| 2005-03-31 | AU$15.23 Million ≈ $10.77 Million |
+18.43% |
| 2004-03-31 | AU$12.86 Million ≈ $9.10 Million |
+31.58% |
| 2003-03-31 | AU$9.77 Million ≈ $6.91 Million |
-3.85% |
| 2002-03-31 | AU$10.16 Million ≈ $7.19 Million |
+462.06% |
| 2001-03-31 | AU$1.81 Million ≈ $1.28 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aroa Biosurgery Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5821337600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$133.44 Million | 157.75% |
| Other Comprehensive Income | AU$9.36 Million | 11.07% |
| Total Equity | AU$84.59 Million | 100.00% |
Aroa Biosurgery Ltd Competitors by Market Cap
The table below lists competitors of Aroa Biosurgery Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
COPRD
NYSE MKT:COPRD
|
$150.91 Million |
|
Atlantic Lithium Ltd
AU:A11
|
$151.02 Million |
|
SKP Resources Bhd
KLSE:7155
|
$151.02 Million |
|
Clavister Holding AB (publ.)
ST:CLAV
|
$151.03 Million |
|
Boab Metals Ltd
AU:BML
|
$150.89 Million |
|
Condor Energies Inc.
TO:CDR
|
$150.86 Million |
|
Alam Sutera Realty Tbk
JK:ASRI
|
$150.83 Million |
|
Kotra Industries Bhd
KLSE:0002
|
$150.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aroa Biosurgery Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 87,079,495 to 84,591,966, a change of -2,487,529 (-2.9%).
- Net loss of 3,465,103 reduced equity.
- Share repurchases of 1,347,691 reduced equity.
- New share issuances of 9,088 increased equity.
- Other comprehensive income decreased equity by 80,194.
- Other factors increased equity by 2,396,371.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-3.47 Million | -4.1% |
| Share Repurchases | AU$1.35 Million | -1.59% |
| Share Issuances | AU$9.09K | +0.01% |
| Other Comprehensive Income | AU$-80.19K | -0.09% |
| Other Changes | AU$2.40 Million | +2.83% |
| Total Change | AU$- | -2.86% |
Book Value vs Market Value Analysis
This analysis compares Aroa Biosurgery Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 104.37x to 2.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-03-31 | AU$0.01 | AU$0.62 | x |
| 2019-03-31 | AU$0.04 | AU$0.62 | x |
| 2020-03-31 | AU$0.21 | AU$0.62 | x |
| 2021-03-31 | AU$0.18 | AU$0.62 | x |
| 2022-03-31 | AU$0.27 | AU$0.62 | x |
| 2023-03-31 | AU$0.28 | AU$0.62 | x |
| 2024-03-31 | AU$0.25 | AU$0.62 | x |
| 2025-03-31 | AU$0.25 | AU$0.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aroa Biosurgery Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.50%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 1.17x
- Recent ROE (-4.10%) is above the historical average (-8.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 95.83% | 0.00% | 0.00x | 3.06x | AU$1.44 Million |
| 2014 | -19.34% | -167.45% | 0.10x | 1.11x | AU$-2.22 Million |
| 2015 | -23.34% | -206.13% | 0.10x | 1.08x | AU$-2.31 Million |
| 2016 | -21.87% | -189.93% | 0.11x | 1.08x | AU$-1.88 Million |
| 2017 | -11.51% | 0.00% | 0.00x | 1.04x | AU$-1.35 Million |
| 2018 | -66.67% | -12.20% | 0.68x | 8.09x | AU$-1.36 Million |
| 2019 | 7.78% | 4.12% | 0.57x | 3.29x | AU$-255.85K |
| 2020 | -9.01% | -23.76% | 0.29x | 1.31x | AU$-11.95 Million |
| 2021 | -32.84% | -85.98% | 0.28x | 1.36x | AU$-23.00 Million |
| 2022 | -8.35% | -21.13% | 0.35x | 1.12x | AU$-17.13 Million |
| 2023 | -0.39% | -0.62% | 0.54x | 1.14x | AU$-9.91 Million |
| 2024 | -11.19% | -15.39% | 0.62x | 1.17x | AU$-18.46 Million |
| 2025 | -4.10% | -4.50% | 0.78x | 1.17x | AU$-11.92 Million |
Industry Comparison
This section compares Aroa Biosurgery Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $67,053,809
- Average return on equity (ROE) among peers: -35.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aroa Biosurgery Ltd (ARX) | AU$80.93 Million | 95.83% | 0.18x | $150.91 Million |
| 4DMEDICAL Ltd (4DX) | $64.24 Million | -46.81% | 0.48x | $1.63 Billion |
| Adherium Ltd (ADR) | $-4.76 Million | 0.00% | 0.00x | $7.37 Million |
| Atomo Diagnostics Ltd (AT1) | $-5.47 Million | 0.00% | 0.00x | $13.76 Million |
| Avita Medical Inc (AVH) | $5.12 Million | -224.74% | 0.50x | $132.15 Million |
| Anteris Technologies Global Corp (AVR) | $22.64 Million | -106.07% | 0.18x | $570.83 Million |
| Control Bionics Ltd (CBL) | $5.05 Million | -38.22% | 0.07x | $18.95 Million |
| Cardiex Ltd (CDX) | $4.88 Million | 56.04% | 0.31x | $13.23 Million |
| Compumedics Ltd (CMP) | $8.51 Million | 8.89% | 1.37x | $41.70 Million |
| Cochlear Ltd (COH) | $503.28 Million | 35.79% | 0.47x | $4.60 Billion |
About Aroa Biosurgery Ltd
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more